4527
Fiscal year ends March Quarters are offset from the calendar — Q1 is Apr–Jun

Rohto Pharmaceutical Co., Ltd. is a health and beauty care company that manufactures and sells products across five main segments: eye care, skin care, internal medicine and food, medical, and other. Its eye care portfolio includes eye drops and eye washes, while skin care products comprise topical medicines, lip creams, sunscreens, and functional cosmetics. The internal medicine and food segment covers gastrointestinal drugs, traditional Chinese medicine, and supplements. The medical segment includes contract development and manufacturing organizations (CDMO) services and ophthalmic pharmaceuticals, alongside other products such as in-vitro diagnostic kits. The company operates globally through regional subsidiaries, including Mentholatum in the Americas, Europe, and Asia-Pacific, and Yu Yung Shing International in Asia for internal medicine and food products. Key subsidiaries in Japan include Rohto Nitten and Qualtech Pharma, which focus on medical products, and Rohto USA and Rohto Brasil in the Americas. In Europe, Mentholatum UK handles business operations, while in Asia, entities such as Rohto Mentholatum Vietnam, Rohto Indonesia, and Tianjin Rohto support regional manufacturing and sales.

Summarised from the annual report, fiscal year ended Mar 2026

Industry Drug Manufacturers - General Homepage rohto.co.jp
Sector Healthcare IR page rohto.co.jp
Tags
eye care, skin care, topical medicines, functional cosmetics, gastrointestinal drugs, traditional chinese medicine, supplements, cdmo, ophthalmic pharmaceuticals, in-vitro diagnostics, Mentholatum, Yu Yung Shing International, Rohto Nitten, Qualtech Pharma, Rohto USA, Rohto Brasil, Mentholatum UK, Rohto Mentholatum Vietnam, Rohto Indonesia, Tianjin Rohto, Mentholatum Asia Pacific, Mentholatum China, Rohto Pharma India, Rohto Mentholatum Bangladesh, Mentholatum Australia, Anz Corporation, Aman Pharmaceutical, Biomimetics Symposia, Offalmos, Rohto Brasil Holdings, Rohto Medilux Europe, Mentholatum Mexico, Mentholatum Taiwan, Soar R2M, Hong Kong Lab
Press page rohto.co.jp/ir/news

Metrics

Valuation  
Market cap ¥ 657.166B
Market cap (USD) $ 4.107B
P/E 18.99
PEG 2.09
P/BV 1.96
P/S 1.83
P/OCF 13.15
P/FCF 29.85
Dividend yield 1.7%
Turnover / mcap —
Returns  
ROE 11.6%
ROI 9.8%
ROIC 8.7%
Profit margin 10.0%
Growth  
Revenue growing Yes
Profits growing Yes
Revenue up 3y Yes
Revenue up 5y Yes
Earnings growth 3y (net profit CAGR) 9.1%
Quality  
Profitable Yes
Margin expanding No
Buying back stock No
Diluting (TTM) No
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 35
Quality score 27.8%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2026 FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013
Revenue 343.725B 308.625B 270.84B 238.664B 199.646B 181.287B 188.327B 183.582B 171.742B 154.599B 167.016B 151.774B 143.822B 129.146B
Net profit 34.247B 31.006B 30.936B 26.377B 21.018B 16.743B 15.41B 9.799B 9.289B 10.011B 9.098B 8.631B 8.947B 8.087B
Free cash flow 21.537B 27.837B 25.333B 21.016B 15.922B 9.704B 12.607B 15.329B 13.702B 9.448B 6.593B — — —

Figure FY 2026 FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013
Share price 2.411K 2.234K 2.969K 2.771K 3.697K 2.953K 2.96K 2.841K 2.976K 2.085K 2.049K 1.709K 1.821K 1.287K
Price performance 12m 0.08 -0.25 0.07 -0.25 0.25 -0 0.04 -0.05 0.43 0.02 0.2 -0.06 0.42 —

Filed figures

Figure Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Balance sheet detail
Trade receivables (JPY) 46.6B 50.3B 44.8B 50.8B 48.2B 85.2B 101B 114B 118B 130B
↳ YoY growth -4.9% +8.1% -11.1% +13.5% -5.2% +76.9% +18.2% +13.5% +2.8% +10.6%
↳ 5y CAGR -0.3% +12.8% +14.9% +20.6% +18.3% +22.0%
Borrowings, current (JPY) 3.35B 4.15B 3.75B 2.11B 2.31B 8.03B 4.18B 5.3B 7.04B 24.7B
Borrowings, non-current (JPY) 1.77B 1.7B 1.42B 5.19B 5.79B 13.4B 7.52B 5.19B 43.2B 28.2B
Bonds payable (JPY) — — — — — — — — 25.4B 25.3B
Lease liabilities (JPY) — — — — — — — — 7.19B 7.31B
Cash and deposits (JPY) 23.9B 30.5B 37.9B 45.3B 53B 72.8B 80B 89.2B 77.2B 86.8B
Intangible assets (JPY) 2.66B 4.11B 3.57B 5.32B 7.54B 9.29B 9.56B 9.22B 56.1B 83.9B
Net debt (borrowings + leases - cash) (JPY) -18.8B -24.7B -32.7B -38B -44.9B -51.4B -68.3B -78.7B -26.9B -26.6B
Cash flow detail
Operating cash flow (JPY) 13.4B 19.2B 21.7B 19B 20B 27.3B 30.9B 34.2B 36.9B 47.8B
Purchases of property, plant and equipment (JPY) -3.78B -5B -6.42B -5.59B -8.72B -10.3B -8.47B -7.98B -9.08B -11.5B
Purchases of intangible assets (JPY) -203M -452M -501M -847M -1.58B -1.06B -1.44B -933M -1.48B -14.8B
Change in receivables (cash effect) (JPY) 1.27B -2.82B 5.34B -4.3B 2.46B -30M -7.56B -6.79B 1.95B -5.18B
Change in inventories (cash effect) (JPY) -827M -2.19B -4.36B 892M 3.19B -3.06B -6.11B -4.03B -4.6B -2.07B
Change in payables (cash effect) (JPY) 165M 3.09B -984M -900M -2.81B 3.32B 1.72B 1.68B -1.29B -141M
Dividends paid (cash effect) (JPY) -2.28B -2.51B -2.51B -3.08B -2.97B -3.42B -4.68B -5.48B -7.07B -9.26B
Share buybacks (cash effect) (JPY) — — — — — — — 0.00 -5B 0.00
Interest paid (cash effect) (JPY) -141M -147M -150M -130M -143M -228M -247M -200M -888M -1.31B
Income taxes paid (cash effect) (JPY) -6.14B -5.17B -5.98B -6.64B -7.8B -8.82B -6.96B -10B -11.2B -11.9B
Operating cash flow before change in receivables (JPY) 12.2B 22B 16.4B 23.3B 17.5B 27.3B 38.5B 41B 35B 53B
Free cash flow (OCF - PPE - intangibles) (JPY) 9.45B 13.7B 14.8B 12.6B 9.7B 15.9B 21B 25.3B 26.4B 21.5B
Income detail
Research and development expense (JPY) 6.15B 6.58B 6.91B 7.08B 7.94B 8.78B 11.1B 13.5B 15B 13.9B
↳ 5y CAGR +6.4% +7.4% +11.1% +14.3% +16.2% +11.8%
Total comprehensive income (JPY) 9.31B 12.2B 6.14B 11.3B 19.8B 26.8B 36.5B 43.6B 35B 48.8B
Comprehensive income to owners (JPY) 9.33B 12.1B 6.26B 11.4B 19.8B 26.6B 36.3B 43.1B 35.2B 47.8B
Provision for credit losses (JPY) 996M 209M 331M 202M 1.21B 1.03B 620M 47M 483M 390M
Credit cost ratio (credit losses / average receivables) (%) 2.1% 0.4% 0.7% 0.4% 2.5% 1.5% 0.7% 0.0% 0.4% 0.3%
Reported Jun 26, 2017 Jun 25, 2018 Jun 28, 2019 Jun 29, 2020 Jun 25, 2021 Jun 28, 2022 Jun 29, 2023 Jun 25, 2025 Jun 19, 2026 Jun 19, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Prompts

Rohto Pharmaceutical Co., Ltd. (ticker 4527), listed in Japan.

ETFs Holding Rohto Pharmaceutical Co., Ltd.

ETF Weight in ETF Shares Market value As of
AVDS 0.12% 27,700 $ 446.27K Nov 16, 2026
DFIS 0.04% 143,752 $ 2.415M Nov 12, 2026
DXIV 0.03% 5,000 $ 84.006K Nov 12, 2026
DFIC 0.02% 217,300 $ 3.651M Nov 12, 2026
DFAX 0.02% 141,800 $ 2.382M Nov 12, 2026
DFAI 0.01% 157,748 $ 2.65M Nov 12, 2026
AVDE 0.01% 100,700 $ 1.622M Nov 16, 2026